Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer
Shana Y. Trostel, Roshan L. Shrestha, John M. Fenimore, Nahoko Sato et al.
Journal
Journal for ImmunoTherapy of Cancer
Topics
Prostate Cancer Treatment and Research
article
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer
Shana Y. Trostel, Roshan L. Shrestha, John M. Fenimore, Nahoko Sato, William L. Dahut, Nicholas T. Terrigino, John R. Bright, Clara C. Y. Seo, Adam G. Sowalsky, Lisa M. Cordes, Meghali Goswami, Ravi Amrit Madan, Anna Baj, Fatima Karzai, Chennan Li, Sunmin Lee, Jeanny B. Aragon-Ching, Kathleen Calzone, Shraddha Rastogi, James L Gulley, S Thomas Hennigan, Jeffrey Schlom, Yi Liu, Min-Jung Lee, Renee N Donahue, William D Figg, Isaiah M King, Jung-Min Lee
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal for ImmunoTherapy of CancerVol. 14(3)
Institutions
Virginia Cancer Institute (US), National Cancer Institute (US)